Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03093688 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Active, Not Recruiting to Recruiting
    • Primary completion date: Dec 31, 2022 to Dec 31, 2030
    • Study completion date: Jun 30, 2023 to Dec 31, 2030
    • Site details revised
    v6
  2. Primary completion date: Dec 31, 2021 to Dec 31, 2022
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Jun 30, 2022 to Jun 30, 2023
    • Site details revised
    v5
  3. Primary completion date: Jul 31, 2019 to Dec 31, 2021
    • Study completion date: Dec 31, 2019 to Jun 30, 2022
    v4
  4. 2 versions Re-verified since Mar 29, 2017, no change to tracked fieldsv2-v3
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Invariant Natural killer T (iNKT) cells are a unique subset of lymphocytes that express homogeneous TCR recognizing KRN7000 which was up-regulated by many kinds of cancer cells. PD-1+CD8+T cells of patients with advanced tumor are most likely tumor-specified. Our hypothesis is that immunotherapy strategy of infusion of iNKT cells and PD-1+CD8+T cells may decrease the tumor burden and improve overall survival. The purpose of this study is to assess the safety and efficacy of treatment of patients with advanced solid tumor by infusing of iNKT cells and PD-1+CD8+T cells.
Trial Details
NCT Number NCT03093688
Lead Sponsor Shanghai Public Health Clinical Center
Conditions
(from sponsor)		 Non-small Cell Lung Cancer, Small Cell Lung Cancer, Pancreas Cancer, Hepatocellular Carcinoma, Gastric Cancer, Renal Cell Carcinoma
Related terms Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Pancreatic Neoplasms, Small Cell Lung Carcinoma, Stomach Neoplasms
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov